Connect with us

Media OutReach

Launch of ixCrypto Fixing EOD Indexes on 2 July 2025

Published

on

HONG KONG SAR – Media OutReach Newswire – 23 June 2025 – IX Asia Indexes, the index business arm of IX Capital International Limited, is pleased to announce the official launch of the ixCrypto Fixing EOD Index* on 2nd July 2025, a new extended benchmark solution designed to meet the growing demand for digital asset valuations in local currencies across Asia. Prior to this, in March 2022, IX Asia Indexes introduced 13 USD-denominated ixCrypto Spot Price Indexes, calculated as the average across 10 quarterly selected leading cryptocurrency exchanges to support fund managers’ pricing needs.

This ixCrypto Fixing EOD Indexes launch marks a major expansion of IX Asia Indexes’ offerings, delivering daily spot-fixed values for five major benchmarks—including the ixCrypto Index, ixBitcoin Index, ixEthereum Index, and the spot price indexes for Bitcoin & Ethereum. (See Appendix 1)

With increasing institutional and retail participation in digital assets across Asia, investors demand for benchmarks that reflect crypto market values in local currencies and at regionally relevant times. The ixCrypto Fixing EOD Indexes datapack is built precisely to serve that need—helping users to better assess digital asset performance in their domestic market context. By applying official exchange rates published by respective local monetary authorities against the U.S. dollar, the ixCrypto fixing EOD indexes provides a fair and standardized daily mark-to-market reference across 13 currencies, including HKD, JPY, KRW, TWD, VND, INR, IDR, AUD, AED, THB, SGD, EUR, and GBP.

Subscribers can download an Excel datasheet from our website featuring:

  • Index values for 5 benchmarks in 13 currencies
  • Applied FX rates with GMT and local timestamps
  • Multi-sheet tabbed format for efficient use

Our ixCrypto Fixing EOD Indexes datapack for each currency is scheduled to be computed 15 minutes after the closing of each respective local financial market session for the day, and the downloadable datasheet is promptly updated from 1:15 p.m to 4:15 a.m after midnight in Hong Kong time. We recommend that subscribers retrieve the latest version from our website after each local market close to access the latest ixCrypto Fixing EOD Index datapack. Full details of each of 13 currencies crypto index fixing time can be found in Appendix 2.

This product is ideal for asset managers, data platforms, analysts, and institutions requiring localized, auditable benchmarks for valuation and structuring.

To learn more about the index series, subscription terms, or partnership opportunities, please contact us at our email: [email protected], our website: www.ix-index.com . Real-time index data can be accessed via Bloomberg terminal with IXCI <GO>.

*EOD refers to End-of-Day. See Appendix 2 for EOD times

Appendix 1
The 5 Major Benchmark Indexes List

Index Full Name IX Asia Indexes Official Index Code Bloomberg Code Bloomberg Code (delayed) Nasdaq Code
ixCrypto Index IXCI IXCI IXCI2 .IXCI
ixBitcoin Index IXBI IXCBI IXCBI2 .IXBI
ixEthereum Index IXEI IXCEI IXCEI2 .IXEI
ixBitcoin Spot Price Index IXBTC IXBTC IXBTC2
ixEthereum Spot Price Index IXETH IXETH IXETH2

Appendix 2
IX Asia ixCrypto Fixing EOD Index Datasheet Update Local Time Schedule

Currency Currency Code Timezone Code Market Closing EOD Time (Local Timezone)* Fixing Time using EOD prices (Local Timezone)** Fixing Time using EOD prices (HKT)
Hong Kong Dollars HKD HKT 16:00 16:15 16:15
Japanese Yen JPY JST 15:00 15:15 14:15
Korean Won KRW KST 15:30 15:45 14:45
Taiwan Dollar TWD TST 13:30 13:45 13:45
Vietnamese Dong VND ICT 15:00 15:15 16:15
Indian Rupees INR IST 15:30 15:45 18:15
Indonesian Rupiah IDR WIB 16:00 16:15 17:15
Australian Dollar AUD AUST 16:00 16:15 14:15
UAE Dirham AED GST 15:00 15:15 19:15
Thai Bhat THB ICT 16:30 16:45 17:45
Singapore Dollar SGD SGT 17:00 17:15 17:15
Euro EUR CEST 17:30 17:45 23:45
Great Britain Pound GBP GMT 16:30 16:45 00:45
United States Dollar USD ET 16:00 16:15 04:15

* Market Closing Time refers to the time when the local financial exchange market closes at the end of day trading.

** Fixing Time using EOD prices refers to the time when the crypto fixing EOD index values are calculated and the datapack is updated approximately.
For reference, 15:15 for JPY means that the ixCrypto fixing index values for 5 selected indexes in JPY are calculated based on 15:00 JST EOD prices and then made available into the datapack at 15:15 JST.

Hashtag: #IXAsia #ixCryptoIndex

The issuer is solely responsible for the content of this announcement.

About IX Asia Indexes and IX Index Advisory Committee

IX Capital International Limited is an award-winning index and investment advisory company. The index business arm- IX Asia Indexes, providing real-time digital asset and innovative indexes, disseminated 24×7 globally and built on robust infrastructure. Since the launch of the first crypto benchmark index (“IXCI”) launched in Hong Kong in December 2018, the ixCrypto index series expand into 29 indexes designed for exchange futures product, mark to market and fund managers’ portfolio construction purposes. To ensure the professionality and impartiality of the index methodologies and operations, IX Asia Indexes has established its index advisory committee with representation from different industries, including fund management, exchanges, brokerage, financial blockchain experts, crypto service providers, etc. The committee will meet quarterly a year to discuss matters relating to the IX Asia Indexes, including to review and to comment the data sources, methodologies, and operations of IX Asia Indexes, to provide guidance to the future development of new IX Asia Indexes and to handle other issues and decisions on an as-needed basis.

IX Asia Indexes was awarded the Fintech Award (wealth investment and management) 2019 and 2021 organised by ETNet. It as well won an award for Startup of the Year and Basic Technology (Big Data) from Hong Kong Fintech Impetus Awards 2022 by Metro Broadcast and KPMG. It also won Asia Pacific Enterprise Achievement Award 2024 by Echolade. IX Asia Indexes has also been named among the 2024 China Brand Innovation Top 100 (Financial Innovation Category) at the Asian Brand Economic Summit (ABEC Beijing 2025). IX Asia Indexes completed its IOSCO compliance statement and obtained ISO/IEC 27001:2013 UKAS certification.

Website:
Advisory Committee:

About IX Crypto Indexes

The ixCrypto index (“IXCI”) is the first crypto index launched in Hong Kong. It was launched on 12 December 2018. It is denominated in USD with a base value of 1000 and a base date on 3 December 2018. Designed to be easy to understand while providing a good representation of the crypto market, ixCrypto index aims to cover the top 80% of the cumulative free-float adjusted market capitalization in the crypto universe and, at the same time, the crypto currencies should fall within the top liquid cryptos ranked by trading volume in the 90 days preceding the review date. The index is to be reviewed quarterly and with a fast entry rule. Real time indexes are disseminated every 5-second for 24×7 since 23 June 2022. Real time index data together with ixBitcoin Index and ixEthereum Index can be obtained from IX Asia Indexes Data Services and Bloomberg terminal on IXCI <GO>. For IXCI, IXBI and IXEI, the indexes are also available through Nasdaq Global Index Data Service (GIDS) with the tickers “IXCI”, “IXBI”, “IXEI”, with dissemination interval kept at 15-second unchanged.

Advertisement

Media OutReach

MIMO: The AI-Native Storage Species Enables Desktop Scale AI Clusters With NVIDIA DGX Spark

Published

on

  • Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.
  • MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.
  • This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.

SINGAPORE –

Professor Zhang Sheng from Tsinghua University Shenzhen International Graduate School expressed a more pragmatic view: “With this solution, we finally no longer have to rely on the university’s data center. Our current annual budget alone is enough to deploy an AI cluster within our lab that better fits our needs—this will significantly boost our research efficiency both technically and operationally. It’s truly fantastic news.”

Asia Debut Marks Industry Inflection Point

Earlier at the 8th China International Import Expo (CIIE), the solution’s core—the world’s first AI-native storage system MIMO—made its strategic Asian debut. Engineered for the AI era, MIMO delivers breakthrough metrics: 400 GB/s bandwidth, 54 million IOPS, and 40–90 μs latency—all within a form factor comparable to a large suitcase.

The platform’s defining Fast-Light-Edge proposition, delivered through its breakthrough architecture, cut through the exhibition noise, generating immediate and widespread attention. MIMO earned exclusive features in top-tier media including Hong Kong Ta Kung Pao and China Securities Journal, while its product demonstration videos gained rapid traction across leading digital channels.

Addressing Foundational Challenges: Technical Dialogues That Matter

During the exhibitions, technical leaders from the United States, Spain, Singapore, Colombia, the UAE (Dubai), India, Pakistan, and Hong Kong SAR engaged in substantive dialogues with Ridger’s Asia team, raising questions that revealed systemic industry gaps:

Architectural Transformation & Strategic Positioning
“Can MIMO fundamentally replace legacy storage architectures—traditional NAS, unified, distributed, and parallel file systems—to deliver accelerated parallel training and high-concurrency inference?”
“With such exceptional performance, would deploying MIMO for traditional enterprise applications represent strategic overinvestment or forward-looking infrastructure?”

Mobile Deployment & Borderless Operations
“MIMO’s suitcase-sized footprint suggests unprecedented mobility. Can it truly accompany research teams globally like standard equipment? How does it maintain operational continuity across jurisdictions? What’s the customs protocol for such ‘technical luggage’?”

Seamless Integration & Global Accessibility
“In scenarios with unnetworked AI servers, can MIMO rapidly establish dedicated training environments with true plug-and-play functionality?”
“Does MIMO integrate transparently with existing AI infrastructure and software stacks without requiring modifications?”
“Beyond Asia-Pacific, what’s the procurement pathway for MIMO? Which currencies and payment methods are accommodated?”

Architectural Breakthrough: Redefining What’s Possible

Addressing these operational realities, Ridger demonstrated MIMO’s system-level value—transcending its role as a storage device to become an architectural cornerstone. MIMO serves as both a high-performance data hub for large-scale GPU clusters and a flexible edge deployment platform, extending seamlessly to desktop environments where it orchestrates workflows with various DGX Spark units based on NVIDIA’s GB10 Grace Blackwell superchip.

Notably, eight global OEM partners—including Dell, HPE, Lenovo, xFusion, H3C, MSI, GIGABYTE, and Acer—have concurrently launched Spark versions based on NVIDIA’s GB10 Grace Blackwell superchip, creating a robust compatibility foundation for MIMO’s ecosystem integration.

This architecture enables independent AI clusters supporting up to 16 computing nodes within constrained environments, managing the complete workflow from large-scale pre-training and fine-tuning to production inference—effectively democratizing enterprise-grade AI capabilities for labs, edge sites, and distributed teams.

As Zhu Ting, an industry observer from Beijing, noted: “This represents the ‘IBM PC moment’ for AI infrastructure—transforming specialized capability into accessible utility.”

Market Validation Through Early Adoption

Market response has been decisive. Following the exhibitions, pioneering organizations across pathological image foundation model development, legal-tech innovation, industrial visual inspection, and naked-eye 3D content production have joined Ridger’s Early Access program, validating the architecture’s transformative potential in real-world operational contexts.

Global Rollout: Accelerating Accessibility

Responding to accelerating global demand, Ridger confirmed the imminent launch of the complete MIMO portfolio and optimized solution bundles for specific DGX Spark configurations through the Ridger Official Global Store. Designed as a frictionless procurement channel, the platform will support diverse payment options including multiple fiat currencies and cryptocurrencies—streamlining access to advanced AI infrastructure.

Organizations seeking deeper understanding of MIMO and its integrated lightweight AI solution with DGX Spark are invited to connect with Ridger team or its strategic partner, NVIDIA Elite Solution Partner SinoInfo.
Hashtag: #Technology #ESG #AI #GPU #Enterprise #Finance #Storage #Flash #Compute #DGX-Spark #NVIDIA #AI-Lab #GDS #NAS #AI-Native



The issuer is solely responsible for the content of this announcement.

Ridger

Ridger is a global technology pioneer building next-generation computing & storage infrastructure for the AI era. Born in the East and operating worldwide, Ridger challenges conventional paths to create new technological paradigms.

The team unites seasoned experts from global storage leaders with visionary AI architects, all driven by a shared mission to democratize cutting-edge technology, rejects incremental improvements and hollow prestige, focusing exclusively on foundational breakthroughs that deliver tangible value and sustainable impact.

From architecture to implementation and from service to empowerment, Ridger provides end-to-end solutions that help clients worldwide ascend to their highest summits.

Continue Reading

Media OutReach

Johnson & Johnson and Asia Pacific Patient Advocacy Group Leaders Unite to Strengthen Shared Decision-Making in Lung Cancer Care

Published

on

Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions[1]

J&J deepens its commitment to patient empowerment in Asia Pacific by launching J&J withMe, a new patient portal offering tailored patient resources, and co-driving market-specific initiatives with patient advocacy groups

SINGAPORE – Media OutReach Newswire – 11 December 2025 – Johnson & Johnson announced the next phase of The 3rd Opinion campaign across Asia Pacific, focused on championing shared decision-making between lung cancer patients and healthcare professionals through events and stakeholder engagements at ESMO Asia 2025 in Singapore.

At a Patient Reception on 6th December 2025, 20 leaders from 17 patient advocacy groups from across Asia Pacific, Europe and the United States shared their support for the need to strengthen shared decision-making. On December 7, 2025, the ESMO Asia 2025 Symposium, ‘Advancing EGFRm NSCLC Treatment Through Shared Decision-Making’ highlighted the role of healthcare professionals not only in making sense of the data but also in helping patients and their families navigate complex decision-making.

“High prevalence in Asia of certain NSCLC mutations makes the choice of first-line therapy absolutely critical. Treatment decisions must balance clinical objectives with patient values — weighing disease biology, survival prospects, durable disease control and the tradeoffs of side effects. That’s why shared decision-making is essential: clinicians should present all appropriate treatment options, so the final choice is collaborative and aligned with each patient’s goals,” said Professor Zhu Zhengfei, Director of the Radiation Oncology Department, Fudan University Shanghai Cancer Center.

“When lung cancer patients are empowered to speak up and understand their options, they are more likely to continue the treatment and their dignity is preserved. Initiatives like ‘The 3rd Opinion’ are vital for fostering truly patient-centered partnerships between people living with cancer and their healthcare teams,” noted Ms. Liu Yiting, Marketing & Branding Director, China MeetHealth Mi-Jian Patient Community.

“The shared commitment validates what many people living with lung cancer have long expressed: shared decision making is essential. From our experience supporting patients, meaningful conversations with clinicians help acknowledge patients’ experiences, address their concerns, and preserving their hopes,” added Mr. Jung-Il Cho, Chairman of Korea Lung Cancer Patients Association.

Our commitment comes off the back of a recent patient survey revealing that 90% of Japanese lung cancer patients want to play an active role in their treatment decisions. The survey also found that shared decision-making, where physicians and patients jointly compare treatment options and decide together, is the strongest driver of treatment satisfaction.1

Patient survey finds that those engaged in shared decision-making were 11 times more likely to report higher satisfaction with their treatments, with 90% of lung cancer patients in Japan wanting to play an active role in their treatment decisions. This finding underscores the importance of shared decision-making and patient-centered care.1

To bridge the gap between patients’ desire to engage in shared decision making and their lack of practical support, J&J has launched “J&J withMe”, an online hub that equips lung cancer patients and caregivers with tailored toolkits and conversation guides to prepare for consultations and make informed, personalized treatment decisions.

Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific said, The 3rd Opinion truly puts patients at the center of care. As part of our deep commitment to address patients’ unmet needs, we will continue partnering with patient advocacy groups and healthcare professionals to help patients to find their voice and the moment when medical advice meets what truly matters to patients.”

图像 (3)

In recognition of diverse cultural and clinical norms across Asia Pacific, J&J has also rolled out tailored market activations in collaboration with local patient advocacy groups:

  • Provision of patient resources such as the “Lung Cancer Book of Answers” in China, ‘Value of Time’ video for patients in Japan, and educational assets in India and Australia/New Zealand;
  • Digital and social media engagement featuring patients and creators discussing the importance of shared decision-making across Singapore, Malaysia, Philippines, Thailand, and Vietnam;
  • Event engagement via the establishment of a patient advisory board in India;
  • Corporate Social Responsibility program with a lung cancer patient group in Korea, bringing employees and patients together to better understand the disease burden of patients and strengthen emotional support for the patient community.

###

About the 3rd Opinion

“The 3rd Opinion”, the patient’s own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[1], [2] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[3] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[4] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[5], [6],[7],[8],[9],[10] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[11] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent.[12],[13] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[14] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[15]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[16].


[1] Johnson & Johnson lung cancer patient quantitative survey conducted in Japan, 2025

[2] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[3] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[4] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

[5] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[6] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[7] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[8] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.

[9] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[10] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

[11] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

[12] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed March 2025.

[13] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

[14] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65

[15] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.

[16] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[17] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.

Hashtag: #Johnson&Johnson

The issuer is solely responsible for the content of this announcement.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at or at . Follow us at .

Johnson & Johnson Innovative Medicine Asia Pacific, a division of Johnson & Johnson International (Singapore) Pte. Ltd is a Johnson & Johnson company.

© Johnson & Johnson International (Singapore) Pte. Ltd. [2025] All rights reserved.

Continue Reading

Media OutReach

Skychakra Global Capital Strategy Upgrade: Advancing Cross-Border Listings and RWA Ecosystem

Published

on

HONG KONG SAR – Media OutReach Newswire – 11 December 2025 – Skychakra Group recently held a grand inauguration ceremony at the Hong Kong International Center, announcing the official acceleration of its globalization strategy. With a mission to “enhance individual energy, empower enterprise growth, and promote asset capitalization,” Skychakra simultaneously launched three major international initiatives: a cross-border listing incubation system, an RWA (Real World Assets) technology ecosystem, and the international upgrade of mind-body energy science, building a new economic ecosystem that spans technology, industry, and capital.

As a global hub for innovation and capital, Hong Kong serves as a significant gateway for the activation of Skychakra’s global strategy. This inauguration not only symbolizes the completion of the facility but also marks the comprehensive rollout of Skychakra’s international layout.

Official Launch of Cross-Border Listing Incubation Center

During the inauguration, Skychakra announced the establishment of a cross-border listing incubation center, led by a professional team qualified with SEC, PCAOB, and FINRA credentials, boasting over a hundred projects in cross-border listings. The service scope includes U.S. stocks, Hong Kong stocks, and SPACs. Unlike traditional investment banks and financial advisors, Skychakra offers a “full-link” service for enterprise capitalization, encompassing red-chip structure setup, financial and audit compliance, SEC and Hong Kong Stock Exchange filing guidance, dual-path IPO/SPAC design, market value management, enterprise internationalization guidance, and digital upgrades.

Originally planning to sign contracts for four companies at the conference, Skychakra exceeded expectations by signing 12, demonstrating its strong appeal and industry influence in cross-border listings and capital operations.

RWA Technology Ecosystem: Making Enterprise Assets Visible to the Financial System

Real World Assets (RWA) are becoming the core of global financial transformation. From BlackRock’s launch of tokenized funds to Hong Kong and Singapore incorporating RWA into financial infrastructure, RWAs are transitioning from concept to large-scale implementation. Skychakra emphasizes that small and medium-sized enterprises face common challenges such as lack of recognition for their assets within the financial system, difficulties in cross-border financing, and a lack of transparency in asset value.

The Skychakra RWA ecosystem will provide enterprises with: tokenizable asset identification, asset structuring and entitlement, on-chain mapping and minting, cross-border compliance design, global issuance and liquidity channels, and on-chain risk control and transparent tracking. The core value of RWA lies in reducing friction for enterprises in connecting to global capital, enhancing asset liquidity and valuation potential.

A Holistic Growth Model: “From People to Enterprises, From Enterprises to Capital”

Skychakra’s differentiated advantage stems from its foundational logic of “starting with people.” The Skychakra energy courses utilize scientific equipment to measure energy fields, emotional frequencies, and meridian states, assisting individuals in enhancing stability, insight, and decision-making abilities.

Based on this foundation, Skychakra constructs three major systems:

1. Enterprise Growth System: Enhancing organizational capabilities, introducing international business, and providing capital operation guidance.

2. Capitalization System: Building global financing capabilities through listings and RWA structures.

3. Asset Digitalization System: Making enterprise value quantifiable, verifiable, and tradable.

These three systems dynamically interact in a spiral structure, forming Skychakra’s unique full-link growth ecosystem.

Conclusion: Global Layout for Greater International Influence

The inauguration of Skychakra’s Hong Kong International Center signifies the official implementation of the group’s globalization strategy. Looking forward, the focus will be on Hong Kong as the core, with Asia as the main axis, while establishing deep collaborations with the North American and Middle Eastern markets. Through this global layout, Skychakra is creating a new organizational model that transcends regions, industries, and capital, enabling enterprises to achieve value flow in the global market and allowing more Asian companies to gain a stronger voice on the international stage.

Hashtag: #Skychakra

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending